Day 2 Flashcards
1
Q
- Immune Checkpoint Inhibitors (ICI’s) have revolutionized how cancer is managed. Instead of suppressing the immune system (like chemo), ICI’s ______the immune system to attack the cancer
A
activate
2
Q
- Immune checkpoint inhibitors are a subgroup of therapies. The larger class of these medications is known as____________.
A
immunotherapies
3
Q
- ICI’s target cell membrane proteins like PD-, PD-LI, and CTLA-4
A
True
4
Q
- ICI’s unleash the immune system on tumors, demonstrating durable clinical responses across ______tumor types.
A
several
5
Q
- In some tumor types, PD-Li testing is not necessary to receive an immune checkpoint inhibitor
A
True
6
Q
- Caris will use the appropriate antibody clone, IHC staining system, and scoring method on all orders.
A
True
7
Q
- If______is compromised, cells accumulate mutations, creating microsatellite instability, causing genomic instability and tumor development.
A
MMR
8
Q
- Tumors with high_____have lots of mutations.
A
Microsatellite Instability (MSI-H)
9
Q
- In some cancers like colon and endometrial, MSI_H is the go-to marker to predict _____ efficacy.
A
ICI
10
Q
- Publications show that MSI is a useful indicator for predicting response to pembrolizumab across all solid tumors.
A
True
11
Q
- By performing both NGS and IHC sequencing, you can get a more ________ view of what is happening.
A
Comprehensive
12
Q
- PD-L1, MSI, MMR, and TMB testing is included with the following Caris test?
A
MI TUMOR SEEK HYBRID + IHC
13
Q
- In metastatic breast cancer estrogen/progesterone receptor positive…ER/PR status may change over time, with exposure to therapy?
A
True
14
Q
- ER/PR positive breast CA pts receive _________ therapy until a clinician deems the malignancy “hormone refractory”.
A
Endocrine
15
Q
- Genomic studies involving breast cancer showed that roughly 36% had _____ mutations.
A
PIK3CA
